Immunic, inc. announces private placement of up to $240 million

New york , jan. 5, 2024 /prnewswire/ -- immunic, inc. (nasdaq: imux) ("immunic" or the "company"), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced it has entered into a securities purchase agreement with select accredited investors to purchase shares of common stock (or pre-funded warrants in lieu thereof) in a three-tranche offering. the first tranche is an upfront payment of $80 million at $1.43 per share, which is expected to close on january 8, 2024, subject to customary closing conditions.
IMUX Ratings Summary
IMUX Quant Ranking